Health and medical to Brazil
Trends and opportunities
The market
Brazil is a complex market to navigate but represents significant
opportunities for Australian companies.The market potential is huge, and
this article details some of the key opportunities.
Brazil is the largest economy in Latin America and the 9th biggest in the
world. Brazil’s healthcare market is the largest in the region and has
undergone significant changes in recent years. Brazil has over 6,000
hospitals, of which 70% are private, 409,000 hospital beds, and 467,000
doctors
[1]
. Private hospitals have expanded and modernized to improve efficiency and
provide better quality medical services, and approximately 80% of the
medical equipment they use is imported
[2]
.
Brazil has a system of free and universal public health. Taxes paid by
Brazilians cover all types of consultations and treatments offered by the
Unified Health System (SUS) without charging any additional fee. The SUS is
a fundamental structure for healthcare in Brazil, as a large proportion of
the population is not able to access the private system.
Approximately 25% of the population has access to private healthcare
[3]
. Generally private health insurance is paid as a benefit to the employee
and his family, which has helped to increase the number of people with
access to better healthcare. Payment in Brazil is made through pay per
service, but in order to reduce unnecessary costs, there are some
discussions around implementation of a pay for performance system. The
National Health Agency (ANS), establishes a list of procedures and prices
that private insurance companies must provide to their members.
According to the World Bank, in 2017 private and public health expenses in
Brazil corresponded to 9.1% of the GDP.
With a consumer market of some 140 million, it represents opportunity for
Australian exporters across the board, including in health and medical
technologies.
Australian companies CSL Behring, ALS Life Sciences, SDI and AD Instruments
are established in Brazil, and many others exporting to the market.
To address the increasing prevalence of chronic diseases and a rising
demand for better healthcare services, the Brazilian Ministry of Health has
prioritized the digitalization of the SUS and has made significant
investment in R&D for the development of innovative drugs and
treatments. In recent years, Brazil’s healthcare market has opened up to
foreign ownership in hospitals and clinics, and norms and standards of the
sector are being harmonized to international standards to facilitate
technology transfer and trade.
Brazil is a member of the Medical Devices Single Audit Program (MDSAP), in
conjunction with Australia, US, Japan and Canada, which defines an
international single regulatory audit program performed by an authorized
auditing organisation. This makes it easier for Australian medical devices
companies to expedite processes of approval to sell into the country.
Brazil also joined the Global Digital Health Partnership (GDHP) along with
a selected group of 13 countries. This initiative is led by the Australian
Digital Health Agency (ADHA) and is a collaboration of governments,
government agencies and the World Health Organisation to support effective
implementation of digital health services around the globe.
Austrade has a proactive strategy to encourage more collaboration between
Australia and Brazil, in the export of Australian technology and services,
in the opportunity for Brazilian health and medical corporations to invest
in Australia, and for more joint research development. We see opportunity
in digital health, medical devices, pharmaceuticals and biotechnology.
Brazil is a member of the Medical Devices Single Audit Program (MDSAP), in
conjunction with Australia, US, Japan and Canada, which defines an
international single regulatory audit program performed by an authorized
auditing organisation. This makes it easier for Australian medical devices
companies to expedite processes of approval to sell into the country.
Brazil also joined the Global Digital Health Partnership (GDHP) along with
a selected group of 13 countries. This initiative is led by the Australian
Digital Health Agency (ADHA) and is a collaboration of governments,
government agencies and the World Health Organisation to support effective
implementation of digital health services around the globe.
Austrade has a proactive strategy to encourage more collaboration between
Australia and Brazil, in the export of Australian technology and services,
in the opportunity for Brazilian health and medical corporations to invest
in Australia, and for more joint research development. We see opportunity
in digital health, medical devices, pharmaceuticals and biotechnology.
Opportunities
Digital Health
The sheer size of Brazilian healthcare market offer tremendous potential to
use digital health to modernize and update their healthcare system.
The Ministry of Health announced possible investments of more than US$ 450m
by 2019 to digitalize the public basic care units of the country’s Unified
Health System (SUS). Private hospitals are also investing in technology and
several new hospitals are obtaining international certificates for data
management and reduction of paper use.
Among the most significant challenges in digital health in Brazil are high
costs (alterations to premises, connectivity, equipment, training and
communication); the country’s continental size and shortage of human
resources to provide training in ICT for health.
Brazil has an immense potential for everything related to remote care,
especially in remote areas with rural populations where there are fewer
doctors and less infrastructure. The main drivers and motivators are
related to costs of maintaining service units with qualified professionals,
difficult access in several areas, the high cost of equipment and the
transmission of knowledge and experience.
Australian expertise in this area can significantly contribute to build and
improve digital health capabilities in the country.
In July 2018, Brazil joined the Global Digital Health Partnership along
with a selected group of 13 countries. This initiative is currently led by
the Australian Digital Health Agency (ADHA) and is a collaboration of
governments, government agencies and the World Health Organisation to
support effective implementation of digital health services.
Medical Devices
Brazil is the largest medical device market in Latin America, considering
both local and multinational healthcare companies. The domestic production
largely consists of low to medium end devices and is mainly focused towards
the local market, whereas the high end medical devices and equipment are
mostly supplied by foreign companies. The norms and standards of the sector
have been harmonised to internationally accepted regulations for ease in
transferring technology and conducting trade on a global level.
Opportunities exists in areas such as: diagnostics and monitoring equipment
(innovative products to replace bigger and more expensive maintenance
equipment), laboratory equipment, orthopedics, implants and new biomedical
and advanced medical devices.
Pharmaceutical market
Brazil is the world’s 6th largest pharmaceutical market and
fastest growing market in Latin America. The value of the Brazilian
pharmaceutical market is about US$ 30,670 million.
The Brazilian pharmaceutical market comprises 392 companies, over 50,000
pharmacies and more than 500 distributors of pharmaceutical products.
Opportunities for Australian companies include large local pharmas actively
seeking collaboration with other biotechs and pharmas to bring innovative
therapeutic options to Brazil (e.g. new molecules, technologies,
incremental innovation) in very flexible business model such as:
co-development, licensing, distribution and so forth.
The production of generic medicines is growing rapidly in Brazil with
approximately 2,000 new products registered every year. The low-cost
generic and biosimilar sectors will play an even greater role, as the
Brazilian government seeks to find cost-effective treatments and suppress
copy medicines.
Biotechnology
Brazil is one of the most promising countries for biotechnology and is well
placed to be a major player and partner in building global value in the
bio-business arena. Home to almost 20% of the world’s genetic and chemical
biodiversity, Brazil is internationally recognized for its scientific
competence in health research. The country turns to bio-business as it
witnesses the emergence of many promising start-up companies. The
confluence of government support, a mature scientific community and a
blooming venture capital industry, has contributed to making Brazil an
excellent place for collaboration and investments in biotech.
The development of the biotech sector is a focus for the Brazilian
government in the coming years, with investments of over R$ 200 billion in
several programs through Brazilian Development Bank (BNDES) and Brazilian
Innovation Agency (FINEP) to support research, development and innovation
plans in areas such as Oncology, Antiinfectives, Metabolic Disorders,
Central Nervous System and so forth.
Registration of health and medical products in Brazil
Medical device manufacturers need to obtain ANVISA (Brazilian Health
Surveillance Agency) approval prior to selling their products in Brazil.
Brazil has four classes of devices with ascending risk, and two
registration pathways: ‘Cadastro’ and ‘Registro’
The ‘Cadastro’ registration is for lower risk devices, has a
simplified application, and typically takes less time than ‘Registro’ .
Product Classification
Devices are classified into four classes based on risk (Class I-IV).
-
Class I (low risk)
– Non-invasive products (around 3 months for approval)
-
Class II (medium risk)
– Invasive products (around 3 months for approval)
-
Class III (high risk)
– Surgical products (around 3 months for approval)
-
Class IV (maximum risk)
– permanent implants and surgical products for long-term use with
direct contact with the central nervous system, coronary system or
biological absorbed. (from 8 - 15 months to up to 3 years)
Comparison between risk classifications for Medical Devices (ANVISA X CE Mark X FDA)
All classes require ANVISA approval |
ANVISA |
CE Mark |
FDA |
|
I |
I |
I |
|
II |
IIa |
II |
|
III |
IIb |
III |
|
IV |
III |
III |
Market entry
Austrade strongly recommends that Australian exporters obtain professional
legal and accounting advice before conducting business in Brazil. Austrade
can provide referrals to service professionals.
In order to succeed in Brazil, a sound business plan, a longer-term
strategy and some degree of local presence is required. Important points to
address include:
-
Setting up a local subsidiary or through a merger/JV or acquisition. It
involves the process of registering subsidiary and products in order for
the Australian company to start bringing products into Brazil.
-
Identification of a local distributor that will market and distribute
the products through different channels and regions in the country. In this
case the licensed distributor owns the registration of the product.
-
A smaller number of exporters establish representative offices due to
the high costs involved and needs that cannot be met by local agents or
distributors. Examples include but are not limited to: businesses that need
a high degree of control over their products and after-sales service or
have commercially sensitive intellectual property.
- Identification of a properly licensed company, that acts as a neutral
agent to hold the registration on behalf of the foreign manufacturer
enabling them to export and distribute the products into Brazil through
different distributors.
Tariffs and Regulation
The Brazilian legislation mandates that all medicine devices &
equipment and medicines should be approved by the Brazilian Health
Surveillance Agency (ANVISA).
This is a bureaucratic and drawn out process which could require waiting
time depending on the classification of the product. Consequently, players
who want to commercialize products in Brazil have to take a medium to long
term view.
Tariffs and duty rates are constantly revised and are subject to change
without notice.
Austrade strongly recommends you to reconfirm these prior to selling to
Brazil.
Key Healthcare events in Brazil
Global Summit Telemedicine & Digital Health
4-6 April 2019
São Paulo
http://telemedicinesummit.com.br/en/
Hospitalar Trade Show, Brazil
Largest healthcare tradeshow in Latin America
São Paulo
21-24 May 2019
http://www.hospitalar.com/en/
FCE Pharma, Brazil
Main tradeshow for the pharmaceutical sector in Latin America
São Paulo
21-23 May 2019
http://www.fcepharma.com.br/en/
Bio Latin America 2019
Main trade show for the Biotechnology sector in Latin America
São Paulo
Dates TBC
https://www.bio.org/events/conferences/bio-latin-america-conference
Links and resources
ANVISA (Brazilian Health Surveillance Agency) www.anvisa.gov.br
ABIMO (Brazilian Medical Devices Manufacturers Association) –
http://brazilianhealthdevices.com.br
ABIMED (Brazilian Association for the High End Technology Health Medical
Devices & Equipment Manufacturers and Importers) - http://www.abimed.org.br
Business Monitor International –
http://www.businessmonitor.com/
World Atlas –
http://www.worldatlas.com/articles/countries-with-the-biggest-global-pharmaceutical-markets-in-the-world.html
The National Bank for Economic and Social Development – http://www.bndes.gov.br
Opportunities and Challenges ICT Industry in Brazil –
http://www.s-ge.com/en/filefield-private/files/60917/field_blog_public_files/69663
World Atlas - Biggest Pharmaceutical Markets in the World by Country 2016
______________________________
[1] National Registration of Health Establishments (CNES), Ministry of
Health, 2017
[2] Brazilian Association of Private Hospitals (ANAHP), 2017
[3] National Health Agency (ANS), 2017
Please note: This list of websites and resources is not definitive. Inclusion in this list does not imply endorsement by Austrade. The information provided is a guide only. The content is for information and carries no warranty; as such, the addressee must exercise their own discretion in its use. Australia’s anti-bribery laws apply overseas and Austrade will not provide business related services to any party who breaches the law and will report credible evidence of any breach. For further information, please see foreign bribery information and awareness pack.
Contact details
The Australian Trade and Investment Commission – Austrade – contributes to Australia's economic prosperity by helping Australian businesses, education institutions, tourism operators, governments and citizens as they:
- develop international markets
- win productive foreign direct investment
- promote international education
- strengthen Australia's tourism industry
- seek consular and passport services.
Working in partnership with Australian state and territory governments, Austrade provides information and advice that can help Australian companies reduce the time, cost and risk of exporting. We also administer the Export Market Development Grant Scheme and offer a range of services to Australian exporters in growth and emerging markets.
For more information on how Austrade can assist you
Call 13 28 78
Submit your enquiry